Jinhe Biotechnology Co., Ltd. Announcement on Subsidiary Obtaining Invention Patent Certificate

MaticHoleFiller · 2026-04-03T01:50:57+00:00

Jinhe Biological subsidiary Jinhe Youben recently received an invention patent granted by the National Intellectual Property Administration. The invention relates to a subunit vaccine that simultaneously expresses two virus proteins, offering advantages such as low cost and high purity. The acquisition of this patent will enhance the company's intellectual property protection and technological competitiveness.

MaticHoleFiller

2026-04-03 01:50:57

Abstract generation in progress

Stock Code: 002688 Stock Short Name: JINHE BIOLOGICAL Announcement No.: 2026-020

Announcement of JINHE Bio-Technology Co., Ltd. regarding its subsidiary’s acquisition of an invention patent certificate

All members of this Company and the Board of Directors warrant that the contents of this announcement are true, accurate, and complete, and assume liability for any false records, misleading statements, or material omissions contained in this announcement.

JINHE Bio-Technology Co., Ltd. (hereinafter referred to as the “Company”)’s subsidiary, JINHE YUBEN Bio-Products Co., Ltd. (hereinafter referred to as “JINHE YUBEN”), has recently obtained an invention patent certificate issued by the National Intellectual Property Administration of the People’s Republic of China. The specific details are as follows:

Certificate No.: No. 8816541
Invention Title: A fusion protein expressing both the BVDV E2 protein and the BRSV F protein, and a bivalent subunit vaccine
Patentee: JINHE YUBEN Bio-Products Co., Ltd.
Address: 010000 Shengle Economic Park, Shengle Fifth Street North, Hohhot, Inner Mongolia Autonomous Region, Horinger County (to the east of the Beiqi Company)
Inventors: Wu Yumei; Li Xuefeng; Kang Bin; Dong Peng; Zhang Jinlong; Zhao Bingwu; Shao Panfeng; Wang Jiafu
Patent No.: ZL 2022 1 1403073.6
Patent Application Date: November 10, 2022
Authorization and Publication No.: CN 116063572 B
Authorization and Publication Date: March 27, 2026

The invention’s innovative implementation allows the production of two types of virus subunit vaccines simultaneously with only one expression process. In addition, the purification filling material and the restriction enzymes used for enzymatic cutting can both be reused repeatedly. The purification process is simple, production costs are low, antigen purity is high, and immunological adverse reactions are effectively reduced. The acquisition of this invention patent is a result of the Company’s continuous innovation. It is conducive to protecting and leveraging the Company’s own intellectual property advantages, forming a sustained innovation mechanism, maintaining a leading position in technology, and enhancing the Company’s core competitiveness. The acquisition of this invention patent will not have a material impact on the Company’s and its subsidiaries’ production and operations.

This is hereby announced.

JINHE Bio-Technology Co., Ltd.

Board of Directors

March 30, 2026

Large-scale information, precise interpretation—available on the Sina Finance App

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.